<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538590</url>
  </required_header>
  <id_info>
    <org_study_id>ologen-Koln</org_study_id>
    <nct_id>NCT00538590</nct_id>
  </id_info>
  <brief_title>Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery</brief_title>
  <official_title>Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pro Top &amp; Mediking Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pro Top &amp; Mediking Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and effectiveness of oculusgen (ologen) collagen matrix implantation
      and Mitomycin-C(MMC) in glaucoma surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the safety and effectiveness in between oculusgen (ologen) collagen matrix
      implantation and Mitomycin-C(MMC) for glaucoma surgery. The surgery is performed by the gold
      standard of trabeculectomy. Mitomycin-C(MMC) is applied for those who not collagen matrix
      implanted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Intraocular Pressure Change</measure>
    <time_frame>360 days</time_frame>
    <description>Postoperative intraocular pressure change at 360 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Intraocular Pressure Change</measure>
    <time_frame>180 days</time_frame>
    <description>Postoperative intraocular pressure change at 180 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Intraocular Pressure Change</measure>
    <time_frame>90 days</time_frame>
    <description>Postoperative intraocular pressure change at 90 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Intraocular Pressure Change</measure>
    <time_frame>30 days</time_frame>
    <description>Postoperative intraocular pressure change at 30 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>360 days</time_frame>
    <description>Incidence (percentage) for complications recorded: Hyphema, early hypotony(&lt;7days), late hypotony(&gt;7days), shallow anterior chamber, choroidal detachment, early leak(&lt;7days), late leak(&gt;7days), Tenon's cysts, and revision surgery for up to 360 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>MITOMYCIN-C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ologen (Oculusgen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Collagen Matrix in Glaucoma Filtering Surgery</intervention_name>
    <description>Collagen Matrix implantation in Glaucoma Filtering Surgery</description>
    <arm_group_label>ologen (Oculusgen)</arm_group_label>
    <other_name>ologen™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C(MMC) and glaucoma filtering surgery</intervention_name>
    <description>If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.</description>
    <arm_group_label>MITOMYCIN-C</arm_group_label>
    <other_name>Mitomycin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Open angle glaucoma

          -  Maxima anti-glaucoma medication failed

          -  Age&gt;18

          -  Able to complete the follow up

        Exclusion Criteria:

          -  Topical eye inflammation

          -  Angle closure glaucoma

          -  Deformity glaucoma

          -  One eye glaucoma

          -  Previous conjunctiva opened

          -  Allergy to collagen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Dietlein, Ph. D, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität Köln</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of Universität Köln</name>
      <address>
        <city>Koln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ologen.com</url>
    <description>ologen collagen matrix website.</description>
  </link>
  <link>
    <url>http://www.nature.com/eye/journal/v24/n9/pdf/eye2010106a.pdf</url>
    <description>Publication on Eye</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <results_first_submitted>January 19, 2012</results_first_submitted>
  <results_first_submitted_qc>April 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2012</results_first_posted>
  <last_update_submitted>April 1, 2012</last_update_submitted>
  <last_update_submitted_qc>April 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ologen</keyword>
  <keyword>collagen matrix</keyword>
  <keyword>glaucoma</keyword>
  <keyword>trabeculectomy</keyword>
  <keyword>Mitomycin-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MITOMYCIN-C</title>
          <description>Application of Mitomycin-C in trabeculectomy to reduce super-scarring.</description>
        </group>
        <group group_id="P2">
          <title>Ologen (Oculusgen)</title>
          <description>The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9">Deceased 8 months after surgery due to known cardiovascular co-morbidity.</participants>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MITOMYCIN-C</title>
          <description>Application of Mitomycin-C in trabeculectomy to reduce super-scarring.</description>
        </group>
        <group group_id="B2">
          <title>Ologen (Oculusgen)</title>
          <description>The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="9.4"/>
                    <measurement group_id="B2" value="64.9" spread="8.6"/>
                    <measurement group_id="B3" value="62.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Intraocular Pressure Change</title>
        <description>Postoperative intraocular pressure change at 360 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
        <time_frame>360 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MITOMYCIN-C</title>
            <description>Application of Mitomycin-C in trabeculectomy to reduce super-scarring.</description>
          </group>
          <group group_id="O2">
            <title>Ologen (Oculusgen)</title>
            <description>The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Intraocular Pressure Change</title>
          <description>Postoperative intraocular pressure change at 360 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="8.7"/>
                    <measurement group_id="O2" value="-11.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: post-operative intraocular pressure change in ologen group is equal to that in Mitomycin-C group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications</title>
        <description>Incidence (percentage) for complications recorded: Hyphema, early hypotony(&lt;7days), late hypotony(&gt;7days), shallow anterior chamber, choroidal detachment, early leak(&lt;7days), late leak(&gt;7days), Tenon's cysts, and revision surgery for up to 360 days.</description>
        <time_frame>360 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MITOMYCIN-C</title>
            <description>Application of Mitomycin-C in trabeculectomy to reduce super-scarring.</description>
          </group>
          <group group_id="O2">
            <title>Ologen (Oculusgen)</title>
            <description>The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Complications</title>
          <description>Incidence (percentage) for complications recorded: Hyphema, early hypotony(&lt;7days), late hypotony(&gt;7days), shallow anterior chamber, choroidal detachment, early leak(&lt;7days), late leak(&gt;7days), Tenon's cysts, and revision surgery for up to 360 days.</description>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="10.1"/>
                    <measurement group_id="O2" value="15.6" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Intraocular Pressure Change</title>
        <description>Postoperative intraocular pressure change at 180 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MITOMYCIN-C</title>
            <description>Application of Mitomycin-C in trabeculectomy to reduce super-scarring.</description>
          </group>
          <group group_id="O2">
            <title>Ologen (Oculusgen)</title>
            <description>The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Intraocular Pressure Change</title>
          <description>Postoperative intraocular pressure change at 180 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="6.1"/>
                    <measurement group_id="O2" value="-11.8" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: post-operative intraocular pressure change in ologen group is equal to that in Mitomycin-C group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Intraocular Pressure Change</title>
        <description>Postoperative intraocular pressure change at 90 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MITOMYCIN-C</title>
            <description>Application of Mitomycin-C in trabeculectomy to reduce super-scarring.</description>
          </group>
          <group group_id="O2">
            <title>Ologen (Oculusgen)</title>
            <description>The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Intraocular Pressure Change</title>
          <description>Postoperative intraocular pressure change at 90 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="5.8"/>
                    <measurement group_id="O2" value="-14.1" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: post-operative intraocular pressure change in ologen group is equal to that in Mitomycin-C group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Intraocular Pressure Change</title>
        <description>Postoperative intraocular pressure change at 30 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MITOMYCIN-C</title>
            <description>Application of Mitomycin-C in trabeculectomy to reduce super-scarring.</description>
          </group>
          <group group_id="O2">
            <title>Ologen (Oculusgen)</title>
            <description>The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Intraocular Pressure Change</title>
          <description>Postoperative intraocular pressure change at 30 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="6.4"/>
                    <measurement group_id="O2" value="-12.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: post-operative intraocular pressure change in ologen group is equal to that in Mitomycin-C group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MITOMYCIN-C</title>
          <description>Application of Mitomycin-C in trabeculectomy to reduce super-scarring.</description>
        </group>
        <group group_id="E2">
          <title>Ologen (Oculusgen)</title>
          <description>The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Stat Methods and limited sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas Dietlein, Ph. D., MD</name_or_title>
      <organization>Hospital of Universität Köln</organization>
      <phone>+49 221 4785862 ext 4300</phone>
      <email>thomas.dietlein@uk-koeln.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

